DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category Archives

Category for old articles

OSCR Oscar Health

oscr-aca-catalyst-report-nov24-2025.html OSCR Breaking News | Oscar Health | Merlintrader ?? ?? OSCR BREAKING CATALYST ACA SUBSIDY EXTENSION November 24, 2025 | Political Healthcare Policy Breakthrough OSCR CATALYST ACUTO ESTENSIONE SUSSIDI ACA 24 Novembre 2025 | Breakthrough Politica Healthcare Executive Summary…

ENLV Enlivex Therapeutics 

Enlivex Therapeutics [finance:Enlivex Therapeutics Ltd.] announced two simultaneous catalysts on November 23-24, 2025, triggering a 74% intraday spike to $1.59: (1) positive 6-month topline data from the Allocetra Phase IIa trial demonstrating durable pain reduction, and (2) a $212M PIPE financing at $1.00/share closing November 25. The clinical data supports Phase IIb progression, but the financing creates massive shareholder dilution (~99%) and introduces governance/crypto risks requiring careful assessment.

ALT Altimmune, Inc.

Altimmune, Inc. (NASDAQ: ALT) is a late-stage clinical biotech company headquartered in Gaithersburg, Maryland, developing pemvidutide (ALT-801), a dual GLP-1/glucagon receptor agonist with a balanced 1:1 mechanism designed for metabolic diseases.

OTLK Outlook Therapeutics, Inc.

Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVA™), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD).

RGNX REGENXBIO 

Currently at channel support , technically a good entry point . REGENXBIO Inc. (RGNX) is facing a landmark FDA decision on February 8, 2026 regarding approval of RGX-121 (clemidsogene lanparvovec), a one-shot AAV gene therapy for MPS II (Hunter Syndrome).

Aldeyra Therapeutics dec 16 PDUFA

Aldeyra Therapeutics (ALDX) – Comprehensive PDUFA Report ?? ?? Aldeyra Therapeutics Ticker ALDX PDUFA Date December 16, 2025 Current Price ~$5.16 Report Date November 21, 2025 ? Executive Summary Aldeyra Therapeutics (ALDX) is approaching a pivotal catalyst: a binary FDA…

NVRI Enviri Corporation

Enviri Corporation Announces Sale of Clean Earth to Veolia for $3.04 Billion and Taxable Spin-Off of Harsco Environmental and Rail Businesses ("New Enviri") to Shareholders

NUVB Oncology Breakout

?? EN ?? IT ✅ NUVB — Oncology Breakout & Commercial Growth Story IBTROZI FDA Approval Success | Q3 Revenue +100% Beat | TRUST-IV Phase 3 Catalyst | $549M Cash | +111% YTD Performance Nuvation Bio — Approved PK activator…

AGIO

AGIO "From Crisis to Recovery: How Dec 7 + Jan 22 PDUFA Decisions Could Drive +80–120% Upside"

KZIA

KZIA Stock Analysis: Biotech Breakthrough in Triple-Negative Breast Cancer | Kazia Therapeutics ?? EN ?? IT ⚡ KZIA — The Breakthrough Moment Immune-Complete Response (iCR) Achieved | Stage IV Metastatic TNBC | +51% Surge on iCR Announcement Kazia Therapeutics —…